NZNian Zhu

Nian Zhu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nian Zhu has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Machine-learning-based classification of diffuse large B-cell lymphoma patients by a 7-mRNA signature enriched with immune infiltration and cell cycle

    by Xujie Zhuang, Bo Liu, Junqi Long, Huina Wang, Jiangyong Yu, Xinchan Ji, Jinmeng Li, Nian Zhu, Lujia Li, Yuhaoran Chen, et al.

    Background Diffuse large B-cell lymphoma (DLBCL) exhibits remarkable heterogeneity but still remains undiagnosed in identifying the subpopulation of DLBCL to predict the prognosis and guide clinical treatment. Methods Molecular subgroups were identified in gene expression data from GSE10846 by a consensus clustering algorithm. And gene set enrichment analysis, immune infiltration, and the proposed cell cycle algorithm were applied to explore the biological functions of different subtypes. Meanwhile, univariate and multivariate Cox regression analyses were used to evaluate independent prognostic factors of DLBCL. Finally, the prognostic model, including some key genes screened by Lasso regression, Random Forest algorithm, and point-biserial correlation, was constructed by an optimal classifier from seven machine learning algorithms and validated by another three external datasets (GSE34171, GSE87371, GSE31312). Results Comprehensive genomic analysis of 1,143 DLBCL samples identify 2 molecularly, prognostically relevant subtypes: immune-enriched (IME) and cell-cycle-enriched (CCE). Then a new predictive model including seven key genes (SERPING1, TIMP2, NME1, DCTPP1, RFC4, POLE2, and SNRPD1) was developed with high prediction accuracy (88.6%) and strong predictive power (AUC = 0.973) based on the Support Vector Machine (SVM) algorithm in 414 patients from GSE10846. The predictive power was similar in another three testing sets (HR > 1.400, p < 0.05). Conclusion This model could evaluate survival independently with strong predictive power compared with other clinical risk factors. Our study constructed a reliable model to predict two new subtypes of DLBCL patients, which could guide the implementation of individualized treatment.


  • Open Access

    A 5-Pathway Signature Predicts Prognosis Based on Immune-Derived lncRNAs in Patients with Breast Cancer

    by Bo Liu, Nian Zhu, Huixia Huo, Junqi Long, Xinchan Ji, Jinmeng Li, Xujie Zhuang, Huina Wang, Lujia Li, Yuhaoran Chen, et al.

    Background. Currently, predictive models were not developed based on the signaling pathway signatures of immune-related lncRNAs in breast cancer (BRCA) patients. Methods. We selected unsupervised hierarchical clustering algorithm to classify patients with BRCA based on the significant immune-derived lncRNAs from the TCGA dataset. And different methods including ESTIMATE, ImmuneCellAI, and CIBERSORT were performed to evaluate the immune infiltration of tumor microenvironment. Using Lasso regression algorithm, we filtered the significant signaling pathways enriched by GSEA, GSVA, or PPI analysis to develop a prognostic model. And a nomogram integrated with clinical factors and significant pathways was constructed to predict the precise probability of overall survival (OS) of BRCA patients in the TCGA dataset (n = 1,098) and another two testing sets (n = 415). Results. BRCA patients were stratified into the PC (n = 571) and GC (n = 527) subgroup with significantly different prognosis with 550 immune-related lncRNAs in the TCGA dataset. Integrated analysis revealed different immune response, oncogenic signaling, and metabolic reprograming pathways between these two subgroups. And a 5-pathway signature could predict the prognosis of BRCA patients between these two subgroups independently in the TCGA dataset, which was confirmed in another two cohorts from the GEO dataset. In the TCGA dataset, 5-year OS rate was 78% (95% CI: 73–84) vs. 82% (95% CI: 77–87) for the PC and GC group (HR = 1.63 (95% CI: 1.17–2.28), ). The predictive power was similar in another two testing sets (HR > 1.20, ). Finally, a nomogram is developed for clinical application, which integrated this signature and age to accurately predict the survival probability in BRCA patients. Conclusion. This 5-pathway signature correlated with immune-derived lncRNAs was able to precisely predict the prognosis for patients with BRCA and provided a rich source characterizing immune-related lncRNAs and further informed strategies to target BRCA vulnerabilities.


  • Four‐gene signature based on machine learning filtration could predict prognosis of patients with breast cancer

    by Bo Liu, Huina Wang, Xin Wang, Junqi Long, Xujie Zhuang, Xinchan Ji, Nian Zhu, Jinmeng Li, Ting Gao, Xuehui Zhang, et al.

    Background: This study aims to propose a breast cancer prediction model for early diagnosis and prognosis management of breast cancer.Objective: In order to explore the pathogenesis of breast cancer and develop accurate breast cancer screening and treatment methods, we have used machine‐learning technologies to conduct an in‐depth study of breast cancer genetic data to obtain new breast cancer signature and prognostic prediction models.Methods: We explored an optimal cluster by unsupervised clustering methods with different expression genes (DEGs) between normal (n = 113) and tumour (n = 1,102) samples. Using least absolute shrinkage and selection operator (LASSO) regression, we selected four biomarkers to develop a predictive model by Cox regression method in the training set (n = 1,083) and validated its predictive accuracy and independence in the testing sets (n = 2,480). Then Gene Set Enrichment Analysis (GSEA) revealed enriched biological pathways in clusters. Finally, we constructed a nomogram including this signature and other significant risk factors to predict survival rates in patients.Results: Four mRNAs (CD163L1, QPRT, NKAIN1 and TP53AIP1) between two clusters from 4,938 DEGs were identified, and then a four‐gene model (risk scores = 0.454*CD163L1–0.360*NKAIN1 + 0.581*QPRT + 0.788*TP53AIP1) was established to divide patients into high‐ and low‐risk group with significantly different prognosis (p < 0.0001) in the training set. Integrated analysis revealed dysregulated molecular processes including predominantly oncogenic signalling pathway, cell cycle and DNA repair in high‐risk group but enriched metabolism pathway in low‐risk group. In addition, this model had similar predictive value (HR >1.60; p < 0.05) in three independent validation sets, which could predict survival independently with more power compared with single clinical factor. In addition, the nomogram could predict the prognosis of breast cancer patients precisely in the training set and another three testing sets.Conclusion: This model could predict prognosis of breast cancer patients precisely and independently, and provide evidence to make treatment decisions and design clinical trials.


  • Open Access

    Integrative analysis identifies three molecular subsets in ovarian cancer

    by Bo Liu, Xinchan Ji, Jinmeng Li, Nian Zhu, Junqi Long, Xujie Zhuang, Huina Wang, Lujia Li, Yuhaoran Chen, Shuangtao Zhao